<SEC-DOCUMENT>0001062993-14-005194.txt : 20140825
<SEC-HEADER>0001062993-14-005194.hdr.sgml : 20140825
<ACCEPTANCE-DATETIME>20140825172014
ACCESSION NUMBER:		0001062993-14-005194
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20140825
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140825
DATE AS OF CHANGE:		20140825

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANAVEX LIFE SCIENCES CORP.
		CENTRAL INDEX KEY:			0001314052
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				208365999
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51652
		FILM NUMBER:		141063261

	BUSINESS ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163
		BUSINESS PHONE:		800-689-3939

	MAIL ADDRESS:	
		STREET 1:		51 W 52ND STREET,
		STREET 2:		7TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019-6163

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Thrifty Printing Inc.
		DATE OF NAME CHANGE:	20050111
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp.: Form 8-K - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES </FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT></B><BR><B>Washington, D.C.
20549 </B></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B><BR><B>Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934 </B></P>
<P align=center>Date of Report (Date of earliest event reported): <B><U>August
25, 2014 </U></B></P>
<P align=center><B><U><FONT size=5>Anavex Life Sciences
Corp.</FONT></U></B><BR>(Exact name of registrant as specified in its charter)
</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><U><B>Nevada </B></U></TD>
    <TD align=center width="33%"><U><B>000-51652 </B></U></TD>
    <TD align=center width="33%"><U><B>98-0608404 </B></U></TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission </TD>
    <TD align=center width="33%">(IRS Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=center width="33%">File Number) </TD>
    <TD align=center width="33%">Identification No.) </TD></TR></TABLE>
<P align=center><B><U>51 West 52</U></B><B><U><SUP>nd</SUP></U></B><B><U>
Street, 7</U></B><B><U><SUP>th</SUP></U></B><B><U> Floor, New York, NY USA 10019
</U></B><BR>(Address of principal executive offices) (Zip Code) </P>
<P align=center>Registrant&#146;s telephone number, including area code
<B><U>1-844-689-3939</U></B><B> </B></P>
<P align=center><B><U>Not Applicable</U></B><B> </B><BR>(Former name or former
address, if changed since last report.) </P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below): </P>
<P align=justify>[&nbsp;&nbsp;&nbsp;]&nbsp;Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425)
<BR>[&nbsp;&nbsp;&nbsp;]&nbsp;Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
<BR>[&nbsp;&nbsp;&nbsp;]&nbsp;Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
<BR>[&nbsp;&nbsp;&nbsp;]&nbsp;Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=justify><B>Item 1.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Entry into a Material Definitive Agreement.
</B></P>
<P align=justify><U>Amendment of Registration Rights Agreement and Convertible
Debentures</U> </P>
<P align=justify style="text-indent:5%">Effective August 25, 2014, Anavex Life Sciences Corp., a Nevada
corporation (the &#147;<U>Company</U>&#148;), amended a Registration Rights Agreement (the
&#147;<U>RRA</U>&#148;) to eliminate all provisions regarding liquidated damages and/or
the accrual of damages with respect to obligations of, and rights enforceable
against, the Company (collectively, the &#147;<U>Amendments</U>&#148;). The RRA was
initially entered into on March 13, 2014 by and between the Company and the
investors signatory thereto (collectively, the &#147;<U>Investors</U>&#148;), as reported
in the Company&#146;s Current Report on Form 8-K filed with the SEC on March 19,
2014.</P>
<P align=justify style="text-indent:5%">The Amendments were effected pursuant to the Company entering
  into an Amendment No. 1 to Registration Rights Agreement with the requisite
  amount of Investors required to amend the RRA, a copy of the form of which is
  attached hereto as <U>Exhibit 10.1</U> and which is incorporated herein in its
entirety by reference.</P>
<P align=justify style="text-indent:5%">In connection with the Amendments to the RRA, the Company
  agreed to adjust the fixed conversion price of the Investors&#146; remaining
  outstanding Senior Convertible Debentures to $0.25 per share. </P>
<P align=justify><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits. </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD vAlign=top width="5%">(a) </TD>
    <TD>
      <P align=justify>Not applicable.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">(b) </TD>
    <TD>
      <P align=justify>Not applicable.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">(c) </TD>
    <TD>
      <P align=justify>Not applicable.</P></TD></TR>
  <TR>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD vAlign=top width="5%">(d) </TD>
    <TD>
      <P align=justify><U>Exhibit No.
Description</U>:</P></TD></TR></TABLE><BR>
<DIV>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
borderColor=#000000 cellSpacing=0 cellPadding=3 width="100%" border=1>

  <TR vAlign=top>
    <TD align=left bgcolor="#CCCCCC" ><B>EXHIBIT NO.</B> </TD>
    <TD width="40%" align=left bgcolor="#CCCCCC"><B>DESCRIPTION</B> </TD>
    <TD width="40%" align=left bgcolor="#CCCCCC"><B>LOCATION</B> </TD>
  </TR>
  <TR vAlign=top>
    <TD align=left ><a href="exhibit10-1.htm">10.1 </a></TD>
    <TD align=left width="40%"><a href="exhibit10-1.htm">Form of Amendment No. 1 to Registration Rights Agreement </a></TD>
    <TD align=left width="40%"><a href="exhibit10-1.htm">Provided herewith </a></TD>
  </TR></TABLE></DIV><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_3></A>
<P align=center><B>SIGNATURES </B></P>
<P align=justify style="text-indent:5%">Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%"><B>ANAVEX LIFE SCIENCES CORP.</B> </TD></TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left width="50%"><I>/s/
      Christopher Missling</I> </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%">Name: Christopher Missling, PhD </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%">Title: President and Chief Executive Officer
  </TD></TR>
  <TR>
    <TD >&nbsp;</TD>
    <TD width="50%">&nbsp; </TD></TR>
  <TR vAlign=top>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="50%">Date: August 25, 2014 </TD></TR></TABLE><BR>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Anavex Life Sciences Corp.: Exhibit 10.1 - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_1></A>
<P align=center><B>AMENDMENT NO. 1 <BR></B><B>TO<BR></B><B>REGISTRATION RIGHTS
AGREEMENT </B></P>
<P align=justify style="text-indent:5%">This Amendment No. 1 to Registration Rights Agreement (this
&#147;<U>Amendment</U>&#148;), dated as of August ___, 2014, is entered into by and
between Anavex Life Sciences Corp., a Nevada corporation (the &#147;<U>Company</U>&#148;),
and the purchaser signatory hereto (the &#147;<U>Purchaser</U>&#148;). Any capitalized
term used herein without definition shall have the definition ascribed to such
term in that certain Registration Rights Agreement, dated March 13, 2014 by and
among the Company and the purchasers signatory thereto (the &#147;<U>RRA</U>&#148;). </P>
<P align=center><B>RECITALS</B> </P>
<P align=justify style="text-indent:5%">WHEREAS, the Company and the Purchaser are currently parties to
the RRA, pursuant to which the Company has granted to the Purchaser certain
registration rights regarding purchased securities; and</P>
<P align=justify style="text-indent:5%">WHEREAS, <U>Section 6(f)</U> of the RRA provides that the RRA
  may be amended by a written instrument signed by the Company and holders of at
least sixty-seven percent (67%) of the Registrable Securities; and </P>
<P align=justify style="text-indent:5%">WHEREAS, the date upon which holders of at least sixty-seven
  percent (67%) of the Registrable Securities have executed written amendments in
  the same form as this Amendment is referred to herein as the &#147;<U>Effective
Time</U>,&#148; and </P>
<P align=justify style="text-indent:5%">WHEREAS, the Company and the Purchaser now desire to amend the
  RRA as provided herein and the Purchaser desires to waive certain rights under
the RRA.</P>
<P align=justify style="text-indent:5%">NOW THEREFORE, in consideration of the mutual promises
  contained in this Amendment and for other good and valuable consideration, the
  receipt and sufficiency of which are hereby acknowledged, the Company and the
  Purchaser, intending to be legally bound, hereby agree as follows: </P>
<P align=center><B>AGREEMENT </B></P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%"  >&nbsp;</TD>
    <TD vAlign=top width="5%">1. </TD>
    <TD>
      <P align=justify><U>Amendment</U>. Upon the Effective Time, the RRA is
      hereby amended to delete any and all references to liquidated damages
      and/or the accrual of damages with respect to obligations of the Company,
      and <U>Section 2(d) </U>shall read in its entirety as follows:</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>&#147;(d) [DELETED]&#148;</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%"></TD>
    <TD>
      <P align=justify>2. <U>Conforming Changes</U>. Upon the Effective Time,
      all references to the term &#147;liquidated damages&#148; and/or &#147;<U>Section
      2(d)</U>&#148; shall be and hereby are deleted from the RRA. Upon the Effective
      Time, all provisions in the RRA and the Transaction Documents and any amendments, attachments,
      schedules or exhibits thereto in conflict with this Amendment shall be and
  hereby are changed to conform to this Amendment.</P></TD></TR></TABLE>
<P align=center>1 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0 BCLLIST>

  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">3. </TD>
    <TD>
      <P align=justify><U>Waiver of Liquidated Damages</U>. The Purchaser hereby
      irrevocably waives, releases and discharges all of its existing claims and
      rights to any and all relief, damages, liquidated damages, and/or
      payments, of any kind under the RRA that exist or have accrued as of the
      Effective Time, including but not limited to any and all damages and/or
      payments related to or accruing pursuant to <U>Section 2(d) </U>of the
      RRA.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">4. </TD>
    <TD>
      <P align=justify><U>Debenture Holding Period</U>. The Company acknowledges
      and agrees that the holding period of the Debentures under Rule 144 of the
      Securities Act shall not change as a result of the transactions
      contemplated hereunder and as such, subject to the Company remaining in
      compliance with the current public information required under Rule 144,
      the Conversion Shares will be eligible for resale pursuant to Rule 144 on
      September 18, 2014.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">5. </TD>
    <TD>
      <P align=justify><U>Form 8-K</U>. The Company shall, on or before 8:30
      a.m., New York City Time, on the second Business Day after the Effective
      Time, file with the Commission a Current Report on Form 8-K describing all
      the material terms of this Amendment in the form required by the Exchange
      Act (the &#147;<U>Form 8- K</U>&#148;). From and after the filing of the Form 8-K,
      the Purchaser shall not be in possession of any material, non-public
      information received from the Company any of its Subsidiaries or any of
      its respective officers, directors, employees or agents, that is not
      disclosed in the Form 8-K. From and after the filing of the Form 8-K, the
      Company confirms that it will have disclosed all material, non-public
      information (if any) regarding the Company and its Subsidiaries delivered
      to the Purchaser by the Company or any of its Subsidiaries, or any of
      their respective officers, directors, employees or agents in connection
      with the transactions contemplated by this Amendment. The Company shall
      not, and shall cause each of its Subsidiaries and each of their respective
      officers, directors, employees and agents, not to, provide the Purchaser
      with any material, non-public information regarding the Company or any of
      its Subsidiaries from and after the Effective Time without the express
      written consent of the Purchaser.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">6. </TD>
    <TD>
      <P align=justify><U>Full Force and Effect</U>. Upon the Effective Time,
      the remainder of the RRA shall not be amended hereby and shall remain in
      full force and effect, except as otherwise set forth in this Amendment.
      The parties hereby ratify and confirm the terms and conditions of the RRA,
      as supplemented and amended by this Amendment.</P></TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">7. </TD>
    <TD>
      <P align=justify><U>Recitals</U>. The Recitals above are true and correct
      and are hereby incorporated by reference.</P></TD></TR>
  </TABLE>
<P align=center>2 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_3></A>
<br>
<TABLE width="100%" border=0 cellPadding=0
cellSpacing=0
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; " BCLLIST>
  <TR>
    <TD width="5%" >&nbsp;</TD>
    <TD vAlign=top width="5%">8. </TD>
    <TD><P align=justify><U>Counterparts</U>. This Amendment may be executed in
      counterparts (including by means of facsimile or electronic transmission),
      each of which shall be deemed an original but all of which, when taken together, will
constitute one and the same agreement. </P></TD>
  </TR>
</TABLE>
<P align=justify>&nbsp;</P>
<P align=center><I>** Signature Pages Follow **</I> </P>
<P align=center>&nbsp;</P>
<P align=center>3 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_4></A>
<P align=justify>IN WITNESS WHEREOF, the Company and the Purchaser have made
and executed this Amendment effective as of the date first indicated above. </P>
<P align=justify><B>&#147;</B><B><U>COMPANY</U></B><B>&#148;: </B></P>
<P align=justify><B>ANAVEX LIFE SCIENCES CORP. </B></P>
<P align=justify>By: ____________________________<BR>Name: Christopher Missling,
PhD. <BR>Title: Chief Executive Officer </P>
<P align=center>&nbsp;</P>
<P align=center>[SIGNATURE PAGE OF PURCHASER FOLLOWS] </P>
<P align=center>&nbsp;</P>
<P align=center>4 </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_5></A>
<P align=center>[SIGNATURE PAGE OF PURCHASER TO RRA AMENDMENT] </P>
<P align=center>&nbsp;</P>
<P align=justify>Name of Purchaser: _____________________________</P>
<P align=justify>Signature of Authorized Signatory of Purchaser:
__________________________</P>
<P align=justify>Name of Authorized Signatory:
_______________________________________</P>
<P align=justify>Title of Authorized Signatory:
________________________________________</P>
<P align=justify>&nbsp;</P>
<P align=center>5 </P>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
